Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 49-54

  Gardiner, Sharon J ^a   Gearry, Richard B ^a   Burt, Michael J ^b   Chalmers Watson, Teresa ^b   Chapman, Bruce A ^b   Ross, Alison G ^b   Stedman, Catherine A M ^b   Huelsen, Alexander ^b   Barclay, Murray L ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

6 mercaptopurine; 6 thioguanine nucleotides; Allopurinol; Azathioprine; Inflammatory bowel disease

Indexed keywords

6 METHYLMERCAPTOPURINE NUCLEOTIDE; 6 THIOGUANINE NUCLEOTIDE; ALLOPURINOL; AZATHIOPRINE; BUDESONIDE; DRUG METABOLITE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ANEMIA; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD TOXICITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE CONTROL; DRUG EFFECT; DRUG POTENTIATION; DRUG WITHDRAWAL; ERYTHROCYTE; ERYTHROCYTE APLASIA; FEMALE; HEMATOCHEZIA; HUMAN; MALAISE; MALE; NAUSEA; PARVOVIRUS INFECTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 78649710356     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06489.x     Document Type: Article

References (30)

1. Garcia-Ortiz RE, De Los Angeles Rodriguez M. Pancytopenia associated with the interaction of allopurinol and azathioprine. J. Pharm. Technol. 1991; 7: 224-6.
2. Boyd IW. Allopurinol-azathioprine interaction. J. Intern. Med. 1991; 229: 386.
3. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann. Pharmacother. 1996; 30: 951-4.
4. Adverse Drug Reactions Advisory Committee. Allopurinol and azathioprine. Fatal interaction. Med. J. Aust. 1980; 2: 130.
5. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplak DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther. 1983; 34: 810-17.
6. Coffey[GET] JJ, White CA, Lesk AB, Rogers WI, Serpick AA. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. Cancer Res. 1972; 132: 1283-9.
7. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996; 61: 1661-2.
8. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther. Drug Monit. 1996; 18: 228-33.
9. Sparrow MP, Hande SA, Friedman S et al. Allopurinol safely and effectively optimizes thioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 2005; 22: 441-6.
10. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 2007; 5: 209-14.
11. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann. Intern. Med. 1995; 123: 132-42.
12. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
13. Dubinsky MC, Yang HY, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
14. Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can. J. Gastroenterol. 2008; 22: 181-5.
15. Ansari A, Elliott T, Baburajan B et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 28: 734-41.
16. Derijks LJJ, Gilissen LPL, Engels LGJB et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease. Ther. Drug Monit. 2004; 26: 311-18.
17. Gearry RB, Barclay ML, Roberts RL et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern. Med. J. 2005; 35: 580-5.
18. Sies C, Florkowski C, George P et al. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. N. Z. Med. J. 2005; 118: U1324.
19. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am. J. Gastroenterol. 1997; 91: 423-33.
20. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981; 30: 239-45.
21. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1998; (3): Art. No.: CD000545. DOI: 10.1002/14651858.CD000545.
22. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 1998; (4): Art. No.: CD000067. DOI: 10.1002/14651858.CD000067.
23. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 2004; 13: 563-7.
24. Gardiner SJ, Begg EJ. Pharmacogenetics testing for drug metabolizing enzymes-is it happening in practice? Pharmacogenet. Genomics. 2005; 15: 365-9.
25. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
26. Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML. Severe hepatotoxicity with high 6-mercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotide concentrations (in press). Eur. J. Gastroenterol. Hepatol. 2008; 20: 1328-42.
27. Coulthard SA, Hogarth LA, Little M et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol. Pharmacol. 2002; 62: 102-9.
28. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J. 2007; 7: 312-7.
29. Duley JA, Chocair PR, Florin THJ. Observations on the use of allopurinol in combination with azathiprine or mercaptopurine [letter]. Br. J. Clin. Pharmacol. 2005; 22: 1161-66.
30. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolisers of thiopurine methyltransferase may differ 3-fold. Clin. Gastroenterol. Hepatol. 2008; 6: 654-60.